Cyclomics has secured an exclusive worldwide license from Oncode Institute for the Sturgeon software, technology and IP. The agreement marks a key step in translating research developed within the Oncode ecosystem into clinical application.

Cyclomics will further develop and integrate Sturgeon into its Epinn platform, supporting real-time cancer classification in clinical settings. The technology was originally developed by Jeroen de Ridder, Oncode Investigator at University Medical Center Utrecht, in collaboration with Bastiaan Tops at the Prinses Máxima Center.

Sturgeon enables rapid molecular classification of central nervous system tumors during surgery. By combining nanopore sequencing with deep learning, the method can deliver results within 20 to 40 minutes, compared to standard diagnostics that can take up to two weeks. This significantly supports faster clinical decision-making in the operating room.

“This agreement marks a major step forward in bringing cutting-edge AI-driven diagnostics from the research setting into routine clinical practice,” said Wigard Kloosterman, CEO at Cyclomics.

“Sturgeon originated from the Oncode Institute ecosystem, which connects leading cancer researchers, clinicians, and data scientists across the Netherlands. For us, this agreement represents a key step in its strategy to ensure that publicly funded cancer research leads to meaningful societal and clinical impact,” said Harma Feitsma, Business Developer at Oncode Institute.

The agreement builds on ongoing collaboration between Cyclomics and UMC Utrecht and reflects the role of Oncode Institute in connecting research, clinical practice and application.

Read the full press release from Cyclomics.